disease-modifying antirheumatic drug


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia, Wikipedia.

disease-modifying antirheumatic drug (DMARD)

a classification of antirheumatic agents referring to their ability to modify the course of disease, as opposed to simply treating symptoms such as inflammation and pain. Agents in this group include auranofin, azathioprine, cycloSPORINE, gold salts, hydroxychloroquine, leflunomide, methotrexate, D-penicillamine, and sulfasalazine.

disease-modifying antirheumatic drug

DMARD Rheumatology Any agent–eg, azathioprine, gold, cyclophosphamide, hydroxychloroquin, and MTX–which slows the rate of joint destruction in rheumatoid arthritis

disease-modifying antirheumatic drug

Abbreviation: DMARD
A drug that is used to treat rheumatoid arthritis and acts more slowly but more effectively than nonsteroidal anti-inflammatory drugs. Such drugs include hydroxychloroquine, methotrexate, and tumor necrosis factor inhibitors.
Synonym: slow-acting antirheumatic drug
See also: drug
References in periodicals archive ?
Calabrese highlighted what he termed a "thoughtful and reassuring" seven-center prospective Italian series involving 31 chronic HCV-infected patients with rheumatoid arthritis (RA) refractory to nonbiologic disease-modifying antirheumatic drugs (DMARDs).
To investigate the relationship between infections and disease activity after adjustment for the effects of drug therapy, analyses on infection rates were done for RA patients from the Consortium of Rheumatology Researchers of North America (CORRONA) database who were on stable doses of disease-modifying antirheumatic drugs, biologic agents, or corticosteroids, according to Dr.
The results from the ongoing study showed that tightly controlled step-up treatment with disease-modifying antirheumatic drugs (DMARDs) can lead to disease remission in routine clinical practice.
All of the patients met the American College of Rheumatology 1987 revised criteria for RA and had active disease despite previous treatment with disease-modifying antirheumatic drugs (DMARDs).
More than 90% used disease-modifying antirheumatic drugs during the study.
It is approved to reduce the signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis (JRA) in patients who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).
BARCELONA -- Treatment of early rheumatoid arthritis with a combination of disease-modifying antirheumatic drugs slows radiographic progression faster in patients without antibodies against cyclic citrullinated peptide than in those with them, Dr.
Medications used to control inflammation include NSAIDs, intra-articular and/or oral steroids, disease-modifying antirheumatic drugs, anti-tumor necrosis factor-[alpha] (anti-TNF-[alpha]) agents, and occasionally anakinra and thalidomide.
BOSTON -- Antibiotic therapy decreases the duration of persistent joint inflammation in Lyme arthritis, and disease-modifying antirheumatic drugs can reduce its severity in individuals with antibiotic-refractory disease, reported Dr.
Scientists analysed the records of patients taking disease-modifying antirheumatic drugs (DMARDs) and those who were not.
Meanwhile, patients continue to take their previous medicines - traditional disease-modifying antirheumatic drugs (DMARDs).
NYSE: PFE) approval for Xeljanz 5 mg twice daily and Xeljanz XR (tofacitinib) extended release 11 mg once daily for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs), the company said.